Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis.

Genomic evolution in myeloproliferative neoplasms reveals distinct pathways to disease progression and therapy-related mutagenesis.

• Why it matters: Understanding the genetic mechanisms underlying disease progression and treatment effects is crucial for improving patient management and preventing transformation to leukemia.
• What they did: Longitudinal whole-genome and targeted sequencing of 30 patients was performed, analyzing clonal dynamics, blood counts, and clinical histories, alongside phylogenetic analysis of 203 haematopoietic colonies.
• The result: Progression involves specific genetic events like TP53 loss and new driver mutations, while stable disease maintains clonal equilibrium; therapy induces characteristic mutations, emphasizing the importance of serial monitoring.